MONROVIA, Calif. , March 13, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release fourth quarter and
MONROVIA, Calif. , Feb. 6, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat , Ph.D., Chief
MONROVIA, Calif. , Dec. 6, 2013 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR) today announced the closing of its initial public offering of 14,639,500 shares of its common stock at an initial public offering price of $5.50 per share, which includes the exercise in full by the underwriters of their
Xencor Prices Initial Public Offering MONROVIA, Calif. , Dec. 3, 2013 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR ) today announced the pricing of its initial public offering of 12,730,000 shares of its common stock at a public offering price of $5.50 per share.
Xencor Files Registration Statement for Proposed Initial Public Offering MONROVIA, Calif., October 11, 2013 Xencor, Inc. today announced the filing of a registration statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of shares of its
MorphoSys and Xencor Provide Update on Phase 1/2a Trial in CLL/SLL for MOR208 (XmAb5574) MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) and US-based Xencor, Inc. today announced completion of the phase 1/2a clinical trial evaluating MOR208 (formerly XmAb®5574) in patients with
MONROVIA, Calif., October 1, 2013—Xencor, Inc. today announced that the first patient has been dosed in the Phase 2a part of its ongoing Phase 1b/2a clinical trial of XmAb®5871 in patients with active rheumatoid arthritis. XmAb5871 is the first in Xencor's class of therapeutic antibodies
Xencor Licenses Fc Antibody Engineering IP to Merck MONROVIA, Calif., July 2, 2013 Xencor, Inc. announced today that that it has entered into a technology license and option agreement to provide Merck, known as MSD outside the United States and Canada, access to one of Xencor's Fc
Monoclonal Antibody with Xencor's High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia MONROVIA, Calif., April 26, 2013 Xencor announced today that MorphoSys AG has dosed the first patient in a Phase 2 clinical trial of MOR208 in B-cell acute lymphoblastic
Xencor Licenses Xtend Therapeutic Protein Half-life Extension Technology to CSL MONROVIA, Calif., and MELBOURNE, Australia, April 16, 2013Xencor, Inc. announced today that Xencor and CSL Limited have entered into a technology license agreement to provide CSL access to Xencor's Xtend™